Fertility News and Research

RSS

New advanced fertility monitor for women

1 in 6 British couples now face problems conceiving, so maximising the chances of natural conception by identifying precisely when ovulation occurs is critical.

4 Nov 2009

Vitrolife takes over sales and marketing management of fertility media in UK and Ireland

Vitrolife (STO:VITR) is taking over management of marketing and sales of fertility media in UK and Ireland. “The acquisition is in line with Vitrolife’s strategy to operate using our own personnel and our own management in the most important markets,” says Magnus Nilsson, Vitrolife’s CEO.

2 Nov 2009

Repros Therapeutics signs settlement agreement with major creditors

Repros Therapeutics today announced that the Company has entered into a settlement agreement with its major creditors for the large majority of the debt incurred associated with the recently suspended Proellex® clinical program.

30 Oct 2009

Leading gynecologist recommends flu shots for pregnant women

Randy A. Fink, MD says pregnant women ought to be shot – with a flu vaccination needle. “A flu shot offers double protection to both mother and baby,” says Dr. Fink, a Miami board certified specialist who was recently named one of “America's Top Obstetrician/Gynecologists” by the Consumer Research Council.

30 Oct 2009

Study shows 62.2 percent of women turn to alternative therapies before medical treatments for infertility

In a recent study from the Ohio State University Medical Center, 62.2 percent of those surveyed turned to alternative therapies before turning to more invasive medical treatments for infertility and getting pregnant.

29 Oct 2009

Fertility Centers of Illinois offers "baby or money back" program

A new study has confirmed anecdotal reports that the recession has caused a decline in fertility treatments across the country. With price being the major deterrent, the report indicates that assisted reproductive technology (ART) such as In Vitro Fertilization (IVF) is sought mostly by affluent, educated, Caucasian women and forecasts a 5% decline in IVF procedures by the end of 2009.

28 Oct 2009

California Cryobank updates its Spanish website

California Cryobank (CCB), an international sperm banking leader, announced today the release of their upgraded Spanish website www.criobanco.com. Criobanco.com offers all the features of CCB's English website www.cryobank.com including online ordering, donor search capability, and extensive information on using donor sperm.

28 Oct 2009

Scientific breakthrough to derive human parthenogenetic stem cell lines from unfertilized human eggs

International Stem Cell Corporation (OTCBB:ISCO) (www.internationalstemcell.com) and Reproductive Medicine Associates of New York (RMA of New York) have shown that immature, unfertilized human eggs can be used to create “parthenotes” from which human parthenogenetic stem cell lines may be derived. Immature eggs are normally discarded during standard in vitro fertilization (IVF) procedures due to their inability to create an embryo.

28 Oct 2009

Clinical results of INVO procedure for treatment of infertility announced

INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.

28 Oct 2009

Aquatrove Biosciences announces positive results from Conceive Plus study

Aquatrove Biosciences, Inc. presented positive results from a study demonstrating that the technology used in Conceive Plus™ may assist trying to conceive couples. These data were recently presented at the 65th Annual Meeting of the American Society for Reproductive Medicine (ASRM).

27 Oct 2009

Schering-Plough announces 2009 third quarter financial results

Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.

22 Oct 2009

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) supports the permissive use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and young men ages 9 to 26, which means that GARDASIL may be given to males ages 9 to 26 to reduce the likelihood of acquiring genital warts at the discretion of the patient's health care provider.

22 Oct 2009

Exposure to stress hormones and chemicals while in the womb can affect male fertility

Exposure to a combination of excess stress hormones and chemicals while in the womb could affect a man's fertility in later life, a study suggests.

22 Oct 2009

Interim study analysis comparing MENOPUR with rFSH in GnRH Antagonist IVF cycles

Ferring Pharmaceuticals presented an interim study analysis indicating that MENOPUR® (menotropins for injection, USP) is effective in in vitro fertilization (IVF) cycles using a gonadotropin-releasing hormone (GnRH) antagonist. The results were presented in a poster at the 65th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Atlanta, October 17-21, 2009.

21 Oct 2009

Complimentary book for fertility patients placing first fertility cycle order

Village Fertility Pharmacy (www.villagefertilitypharmacy.com), a specialty pharmacy focused exclusively on infertility medications, is pleased to announce that, effectively immediately, fertility patients who place a fertility cycle order for the first time will receive a complimentary copy of Kristen Magnacca's award-winning book, "Love and Infertility: Strategies for Survival - Balancing Infertility, Marriage, and Life."

20 Oct 2009

IntegraMed America expands its Attain IVF treatment financing offerings

IntegraMed America, Inc., the nation’s leading manager of specialty outpatient healthcare facilities in the emerging, technology-focused medical niches of fertility and vein care, today announced that it has expanded its Attain™ IVF (In Vitro Fertilization) family of treatment financing offerings to include the Attain IVF Multi-Cycle Program.

20 Oct 2009

Testicular cancer survivors at risk of effective treatment

Testicular cancer survivors can face an increased risk of long-term illness, not because of the malignancy, but the highly effective treatment they receive, according to a study in the urology journal BJUI.

20 Oct 2009

Link between stress reduction and increase in pregancy rate established

Women who participated in a stress management program prior to or during their second IVF cycle had a 160 percent greater pregnancy rate than women who did not participate in a program, according to a study presented today at the American Society for Reproductive Medicine's 65th Annual Meeting.

20 Oct 2009

Rituxan drug effective for treating ANCA-associated vasculitis

Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy.

19 Oct 2009